What is the treatment of choice for a patient diagnosed with Wolff-Parkinson-White Syndrome?

The treatment of choice for Wolff-Parkinson-White (WPW) syndrome is radiofrequency catheter ablation. This procedure involves the use of radiofrequency energy to selectively destroy the accessory pathway that causes the arrhythmias associated with WPW syndrome. This pathway can lead to reentrant tachycardias, which are often the symptomatology in patients with WPW.

Radiofrequency catheter ablation not only eliminates the arrhythmia but also addresses the underlying anatomical issue, providing a long-term solution and significantly reducing the risk of future arrhythmias associated with WPW. The procedure is typically performed in a specialized electrophysiology lab and is considered safe and effective for this condition.

In contrast, other treatment options like verapamil, percutaneous coronary intervention, and digoxin may be used for managing certain types of arrhythmias or heart conditions but are not curative in the context of WPW syndrome. Verapamil, for example, is a calcium channel blocker that can help control heart rate but does not eliminate the abnormal conduction pathway. Similarly, digoxin may provide rate control but carries risks and is not a definitive treatment. Percutaneous coronary intervention is unrelated as it pertains to coronary artery disease rather than the electrical conduction issues